healthcare.digital March 24, 2025
Exec Summary
23andMe’s Chapter 11 bankruptcy process is still in its early stages, with the company initiating a court supervised sale to maximise its shareholder value. While no buyers have been confirmed, several potential candidates have emerged based on the company’s assets, particularly its genetic database of over 15 million customers and the ongoing sale dynamics.
So, will the sale of 23andMe be a merger, acquisition or partnership? Let’s dive in and examine the most likely buyers:
Anne Wojcicki (Independent Bidder)
Working Hypothesis > Wojcicki, the co-founder and former CEO, resigned on March 23, 2025, explicitly to position herself as an independent bidder in the bankruptcy sale. She has been trying to take 23andMe private since April...
Today's Sponsors
Today's Sponsor